JJJoanna Janus

Joanna Janus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joanna Janus has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Jolanta Antoniewicz-Papis

    Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine (IHTM), Indiry Gandhi 14, Warsaw 02-776, Poland

    4 shared publications
  • Katarzyna Chmielewska

    Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine (IHTM), Indiry Gandhi 14, Warsaw 02-776, Poland

    4 shared publications
  • Agata Mikołowska

    Instytut Hematologii i Transfuzjologii

    2 shared publications
  • Karolina Wrzodak

    Instytut Hematologii i Transfuzjologii

    1 shared publication
  • Marta Stącel

    Instytut Hematologii i Transfuzjologii

    1 shared publication

Latest Publications

  • Open Access

    IL-1β, IL-6, IL-2, IL-10 and VEGF stability in autologous and allogeneic serum-based eye drops

    by Joanna Janus, Katarzyna Chmielewska, Agata Mikołowska, Karolina Wrzodak, Marta Stącel, Jolanta Antoniewicz-Papis

    Serum-based eye drops are an effective treatment for dry eye syndrome. Most of the proteins and growth factors in serum are thought to remain stable for several months, but there are no standardized protocols for preparation of the product. Also, the time from thawing to drop administration is of significant importance. Stability testing of IL-1β, IL-6, IL-2, IL-10 and VEGF using flow cytometry was performed. Concentrations in samples thawed prematurely and directly before measurement and before after 5-month storage were studied. Mean concentration in the samples thawed immediately before measurement is higher in VEGF and IL-10 and in samples thawed prematurely concentrations of in IL-1β, IL-2, IL-6. Results for measuring the stability after 5-moth storage were: in most samples the levels of IL-1β and IL-2 interleukins were higher after 5-month storage, while the IL-6 and IL-10 and VEGF were lower. Premature thawing and storage of serum at 20°C significantly alters the concentration of cytokines, which reduces the effectiveness of the serum eye drops. Storing serum at -20°C for several months influences the change in VEGF and the studied cytokines concentration. It is necessary to extend the studies to other serum proteins and to establish a shelf life.

  • Open Access

    What’s new in the field of serum-based eye drops

    by Joanna Janus, Katarzyna Chmielewska, Agata Mikołowska, Jolanta Antoniewicz-Papis

    Worldwide serum-based eye drops are successfully used in the treatment of the Dry Eye Syndrome (DES). Autologous serum eye drops (ASEDs) are most common but allogenic eye drops were introduced in many countries mostly because of the COVID-19 pandemic. Not all aspects of the product formula have however been worked out so far. Each medical entity involved in the preparation, packaging and distribution of the product performs according to its own procedures. Various actions have therefore been undertaken to standardize, harmonize and exchange the experience in this field. In 2022 the 5th edition of EDQM’s Guide to the quality and safety of tissues and cells for human application was issued. Within the EU4Health Programme a new group for Recommendations and Guidance Documents for the Management of Substances of Human Origin (SoHO) in Hospitals is being formed. International cooperation of serumbased product users lead to the establishment of working group events — Workshops on the Eye Drops of Human Origin (EDHO) and Serum eye drop manufacturer’s group. Despite the widespread use of serum-based eye drops all over the world, in almost none of the countries, EU included, are there strict legal regulations for handling the product. It is therefore necessary to come up with a universal definition of artificial tears therapy and to determine specific procedures for the product preparation. Worldwide serum-based eye drops are successfully used in the treatment of the Dry Eye Syndrome (DES). Autologous serum eye drops (ASEDs) are most common but allogenic eye drops were introduced in many countries mostly because of the COVID-19 pandemic. Not all aspects of the product formula have however been worked out so far. Each medical entity involved in the preparation, packaging and distribution of the product performs according to its own procedures. Various actions have therefore been undertaken to standardize, harmonize and exchange the experience in this field. In 2022 the 5th edition of EDQM’s Guide to the quality and safety of tissues and cells for human application was issued. Within the EU4Health Programme a new group for Recommendations and Guidance Documents for the Management of Substances of Human Origin (SoHO) in Hospitals is being formed. International cooperation of serumbased product users lead to the establishment of working group events — Workshops on the Eye Drops of Human Origin (EDHO) and Serum eye drop manufacturer’s group. Despite the widespread use of serum-based eye drops all over the world, in almost none of the countries, EU included, are there strict legal regulations for handling the product. It is therefore necessary to come up with a universal definition of artificial tears therapy and to determine specific procedures for the product preparation.